Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb Trial.
CONCLUSION: These 5-year data establish that SC ABA (125 mg/wk) has a consistent safety profile and durable efficacy for longterm treatment of patients with RA who had an inadequate response to MTX.
PMID: 29657147 [PubMed - as supplied by publisher]
Source: J Rheumatol - Category: Rheumatology Authors: Genovese MC, Pacheco-Tena C, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente RM, Nash P, Simon-Campos JA, Box J, Legerton CW, Nasonov E, Durez P, Elegbe A, Wong R, Li X, Banerjee S, Alten R Tags: J Rheumatol Source Type: research
More News: Abatacept | Arthritis | Cancer & Oncology | Methotrexate | Orencia | Rheumatoid Arthritis | Rheumatology | Study